Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy

BACKGROUND: Inhibitors of immune checkpoints have shown little effect in clinical trials involving glioma patients. Here, we explored novel targets for use in future treatments. Previous studies showed the sialic acid-binding Ig-like lectin (Siglec) family to have a specific role in immunosuppressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Guan-Zhang, Zhang, Ke-Nan, Wang, Zheng, Hu, Hui-Min, Wang, Zhi-Liang, Huang, Ruo-Yu, Jiang, Hao-Yu, Zhai, You, Feng, Yue-Mei, Chang, Yuan-Hao, Li, Ren-Peng, Wu, Fan, Zeng, Fan, Jiang, Tao, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885574/
https://www.ncbi.nlm.nih.gov/pubmed/31819511
http://dx.doi.org/10.2147/OTT.S223406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885574/
https://www.ncbi.nlm.nih.gov/pubmed/31819511
http://dx.doi.org/10.2147/OTT.S223406

Ejemplares similares